Loading clinical trials...
Loading clinical trials...
This phase I trial studies the side effects of 68GA-PSMA-11 PET imaging in patients with prostate cancer that has come back (recurrent). Gallium (68Ga) is a radiotracer that binds to a molecule, PSMA,...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
City of Hope Medical Center
Collaborators
NCT07073794 · Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma, and more
NCT06205316 · Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, and more
NCT05054296 · Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, and more
NCT04777071 · Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, and more
NCT04336943 · Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
City of Hope Medical Center
Duarte, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions